Skip to main content
. 2021 Dec 3;20(12):2577–2584. doi: 10.1158/1535-7163.MCT-21-0201

Figure 1.

Figure 1. KRAS mutational distribution in all NSCLC (A) and adenocarcinoma (B) and squamous cell (C) NSCLC histologies. The prevalence of KRAS mutations was 37.2% among adenocarcinoma and only 4.4% in squamous cell samples, however KRAS mutational distribution was similar in both histologies.

KRAS mutational distribution in all NSCLC (A) and adenocarcinoma (B) and squamous cell (C) NSCLC histologies. The prevalence of KRAS mutations was 37.2% among adenocarcinoma and only 4.4% in squamous cell samples, however KRAS mutational distribution was similar in both histologies.